Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Kernstine, Kemp H.Moon, James
Kraut, Michael J.
Pisters, Katherine M. W
Sonett, Joshua R.
Rusch, Valerie W.
Thomas, Charles R. Jr
Waddell, Thomas K.
Jett, James R.
Lyss, Alan P.
Keller, Steven M.
Gandara, David R.
UMass Chan Affiliations
Quality Assurance Review CenterDocument Type
Journal ArticlePublication Date
2014-08-01
Metadata
Show full item recordAbstract
BACKGROUND: Although preoperative chemotherapy (cisplatin-etoposide) and radiotherapy, followed by surgical resection, is considered a standard of care for superior sulcus cancers, treatment is rigorous and relapse limits long-term survival. The Southwest Oncology Group-Intergroup Trial S0220 was designed to incorporate an active systemic agent, docetaxel, as consolidation therapy. METHODS: Patients with histologically proven and radiologically defined T3 to 4, N0 to 1, M0 superior sulcus non-small cell lung cancer underwent induction therapy with cisplatin-etoposide, concurrently with thoracic radiotherapy at 45 Gy. Nonprogressing patients underwent surgical resection within 7 weeks. Consolidation consisted of docetaxel every 3 weeks for 3 doses. The accrual goal was 45 eligible patients. The primary objective was feasibility. RESULTS: Of 46 patients registered, 44 were eligible and assessable; 38 (86%) completed induction, 29 (66%) underwent surgical resection, and 20 (45% of eligible, 69% surgical, and 91% of those initiating consolidation therapy) completed consolidation docetaxel; 28 of 29 (97%) underwent a complete (R0) resection; 2 (7%) died of adult respiratory distress syndrome. In resected patients, 21 of 29 (72%) had a pathologic complete or nearly complete response. The known site of first recurrence was local in 2, local-systemic in 1, and systemic in 10, with 7 in the brain only. The 3-year progression-free survival was 56%, and 3-year overall survival was 61%. CONCLUSIONS: Although trimodality therapy provides excellent R0 and local control, only 66% of patients underwent surgical resection and only 45% completed the treatment regimen. Even in this subset, distant recurrence continues to be a major problem, particularly brain-only relapse. Future strategies to improve treatment outcomes in this patient population must increase the effectiveness of systemic therapy and reduce the incidence of brain-only metastases.Source
Ann Thorac Surg. 2014 Aug;98(2):402-10. doi: 10.1016/j.athoracsur.2014.04.129. Epub 2014 Jun 28. Link to article on publisher's siteDOI
10.1016/j.athoracsur.2014.04.129Permanent Link to this Item
http://hdl.handle.net/20.500.14038/46465PubMed ID
24980603Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.athoracsur.2014.04.129